Results 51 to 60 of about 5,784 (166)

A Simple Cell Culture Assay for Human Prostatic Branching Morphogenesis Spotlights Bone Morphogenetic Protein Signaling as a Therapeutic Target in Benign Prostatic Hyperplasia

The Prostate, Volume 86, Issue 13, Page 1332-1340, September 15, 2026.
ABSTRACT Background Benign prostatic hyperplasia (BPH) leads to prostate enlargement and lower urinary tract symptoms that can resist treatment. A histologic hallmark of BPH is glandular epithelial hyperplasia with new ductal branching morphogenesis. The stromal inductive factors driving tissue morphogenesis may provide new therapeutic targets, but are
Anna S. Pollack, James D. Brooks, Jonathan R. Pollack   +2 more
wiley   +1 more source

Surgical Debulking Modifies Notch Signaling and May Improve Vismodegib Effectiveness for Locally Advanced Basal Cell Carcinoma

JID Innovations
Smoothened inhibitors, such as vismodegib, exhibit remarkable success in treating patients with locally advanced basal cell carcinoma (LaBCC). Yet, vismodegib efficacy is hindered by notable side effects, which often lead to treatment discontinuation and
Natella Maglakelidze, Samantha L. Gettle, Amy L. Longenecker, Allison T. Vidimos, Elizabeth M. Billingsley, Ryan P. Hobbs, Charlene Lam   +6 more
doaj   +1 more source

The Therapeutic Potential of Purmorphamine Across Disease Models

Journal of Cellular and Molecular Medicine, Volume 30, Issue 17, September 2026.
ABSTRACT Purmorphamine (PUR) is a trisubstituted purine compound that selectively activates Smoothened receptor, thereby initiating Sonic Hedgehog (Shh) signalling—a pathway critical for embryonic patterning, neuronal specification and tissue regeneration across multiple organ systems. Dysregulation of Shh signalling has been implicated in degenerative
Ashis Dhar, Ahnaf Dil Sharar, Saikarthik Papisetty, Mohammad Bydon, F. M. Moinuddin   +4 more
wiley   +1 more source

Vismodegib no Tratamento do Carcinoma Basocelular Avançado – Experiência de 3 Casos

Revista da Sociedade Portuguesa de Dermatologia e Venereologia, 2016
O carcinoma basocelular é a neoplasia cutânea mais comum, e a sua incidência tem vindo a aumentar nas últimas décadas. O tratamento de eleição é a cirurgia, podendo em casos selecionados optar-se pela radioterapia como tratamento de intenção curativa, ou
Ana Gameiro, Miguel Gouveia, Ana Brinca, Maria Manuel Brites, Ricardo Vieira, Américo Figueiredo   +5 more
doaj   +1 more source

Comparative Response of Canine and Human Osteosarcoma Tumour Cell Lines to Molecularly Targeted Anticancer Agents at Clinically Relevant Exposures With Analysis of Genomic Biomarkers

Veterinary and Comparative Oncology, Volume 24, Issue 3, Page 532-544, September 2026.
ABSTRACT Osteosarcoma (OSA) is a primary bone tumour occurring in children but is also prevalent in large breed dogs. Canine OSA (cOSA) has long been viewed as analogous to human OSA (hOSA) with cOSA serving as a surrogate for development of therapeutic approaches to treat the rarer human form.
Daniel L. Gustafson, Kala A. Early, Maritza A. Morales, Klaudia A. Poplawski, Sunetra Das, Dawn L. Duval   +5 more
wiley   +1 more source

Vismodegib CRD from Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies

, 2017
Vismodegib CRD Calculation ...
Xiaoying Chen (268103), Paolo Vicini (2311993), Chandra Vage (706260), Erica L. Bradshaw-Pierce (15007500), Gang Li (34549), Mary E. Spilker (9917407), Ravi Visswanathan (7511996), Shinji Yamazaki (2039911), Judy Lucas (1480975)   +8 more
core   +1 more source

A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis

Journal of Hematology & Oncology, 2018
Background The JAK inhibitor (JAKi) ruxolitinib is standard treatment for myelofibrosis (MF), but some patients are unresponsive. Pre-clinical and clinical data suggest that addition of a Hedgehog pathway inhibitor (HPI) to ruxolitinib might improve ...
Stephen Couban, Giulia Benevolo, William Donnellan, Jennifer Cultrera, Steffen Koschmieder, Srdan Verstovsek, Gregory Hooper, Christian Hertig, Maneesh Tandon, Natalie Dimier, Vikram Malhi, Francesco Passamonti   +11 more
doaj   +1 more source

Treatment of periocular basal cell carcinoma with neoadjuvant vismodegib

American Journal of Ophthalmology Case Reports, 2020
Purpose: To report a case of a locally advanced periocular basal cell carcinoma treated with neoadjuvant Vismodegib therapy prior to surgery. Observations: A 63-year-old female presented to the oculoplastics clinic with biopsy-proven basal cell carcinoma
Maxwell G. Su, Luke B. Potts, Jonathan H. Tsai   +2 more
doaj   +1 more source

Tumor Plasticity and Microenvironmental Crosstalk as Drivers of Metastasis and Therapy Resistance

MedComm, Volume 7, Issue 8, August 2026.
The graphical abstract is a schematic illustration of the bidirectional crosstalk between tumor plasticity and the tumor microenvironment (TME) in driving metastasis and therapy resistance. Tumor‐intrinsic factors such as genetic mutations and epigenetic reprogramming enable dynamic transitions between epithelial, mesenchymal, and cancer stem cell ...
Gunjan Dagar, Manisha Dagar, Ashna Gupta, Anju Surendranath, Suraja Kumar Das, Mohd Umar Rehmani, Mukesh Tanwar, Sameer Mirza, Muzafar A. Macha, Ammira S. Al‐Shabeeb Akil, Shahab Uddin, Mayank Singh, Ajaz A. Bhat   +12 more
wiley   +1 more source

Vismodegib for the treatment of radiation-induced basal cell carcinoma – a case report and brief literature study

, 2019
Vismodegib is playing an increasing role in the treatment of locally advanced or metastatic basal cell carcinoma (BCC) that is not a candidate for surgery or radiotherapy, and also in radiation-induced BCC.
Davide Baldaccini, Andrea Antonuzzo, Fabiola Paiar, Concetta Laliscia   +3 more
core   +1 more source